Literature DB >> 16500131

Requirement of E7 oncoprotein for viability of HeLa cells.

Akiko Nishimura1, Tomomi Nakahara, Takaharu Ueno, Kenta Sasaki, Satoshi Yoshida, Satoru Kyo, Peter M Howley, Hiroyuki Sakai.   

Abstract

Most human papillomavirus (HPV)-positive cervical cancers contain integrated copies of the viral genome in their chromosomes and express the viral oncoproteins E6 and E7. A virus-encoded transcription factor, E2, is known to repress E6/E7 expression in HPV-positive cancer cells, leading to growth inhibition, which indicates that E6/E7 is required for the survival of the cells. We found that the E2-mediated growth inhibition of HeLa cells, an HPV18-positive cancer cell line, was coupled with a reduction in telomerase activity, an effect which was rescued by the complementation of E7 expression, but not E6 expression, indicating that the cell viability and the telomerase activity in HeLa cells are maintained by an E7-associated function. Analysis of E7 mutants suggested that the binding to the pRB family of pocket proteins was involved in the ability of E7 to rescue the growth potential and telomerase activity inhibited by E2 expression. We also showed that the telomerase activity upregulated by E7 expression was determined by the hTERT promoter activity, and that c-Myc upregulation caused by pRB inactivation could account for the promoter activity. The activation of p53 and consequent accumulation of p21Cip1, which were triggered by the downregulation of E6, appeared not to be essential for the E2-mediated growth arrest.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16500131     DOI: 10.1016/j.micinf.2005.10.015

Source DB:  PubMed          Journal:  Microbes Infect        ISSN: 1286-4579            Impact factor:   2.700


  13 in total

1.  HPV E7 contributes to the telomerase activity of immortalized and tumorigenic cells and augments E6-induced hTERT promoter function.

Authors:  Xuefeng Liu; Jeffrey Roberts; Aleksandra Dakic; Yiyu Zhang; Richard Schlegel
Journal:  Virology       Date:  2008-03-26       Impact factor: 3.616

2.  Human papillomavirus E7 repression in cervical carcinoma cells initiates a transcriptional cascade driven by the retinoblastoma family, resulting in senescence.

Authors:  Kimberly Johung; Edward C Goodwin; Daniel DiMaio
Journal:  J Virol       Date:  2006-12-20       Impact factor: 5.103

3.  Requirement for stromal estrogen receptor alpha in cervical neoplasia.

Authors:  Sang-Hyuk Chung; Myeong Kyun Shin; Kenneth S Korach; Paul F Lambert
Journal:  Horm Cancer       Date:  2012-10-13       Impact factor: 3.869

Review 4.  Recent advances in the search for antiviral agents against human papillomaviruses.

Authors:  Amélie Fradet-Turcotte; Jacques Archambault
Journal:  Antivir Ther       Date:  2007

5.  Persistence of high-grade cervical dysplasia and cervical cancer requires the continuous expression of the human papillomavirus type 16 E7 oncogene.

Authors:  Sean F Jabbar; Linda Abrams; Adam Glick; Paul F Lambert
Journal:  Cancer Res       Date:  2009-05-12       Impact factor: 12.701

Review 6.  Molecular mechanisms of human papillomavirus-induced carcinogenesis.

Authors:  Michaël Lehoux; Claudia M D'Abramo; Jacques Archambault
Journal:  Public Health Genomics       Date:  2009-08-11       Impact factor: 2.000

7.  Potent anti-tumor effect generated by a novel human papillomavirus (HPV) antagonist peptide reactivating the pRb/E2F pathway.

Authors:  Cai-ping Guo; Ke-wei Liu; Hai-bo Luo; Hong-bo Chen; Yi Zheng; Shen-nan Sun; Qian Zhang; Laiqiang Huang
Journal:  PLoS One       Date:  2011-03-15       Impact factor: 3.240

8.  Small molecule inhibitors of human papillomavirus protein - protein interactions.

Authors:  C M D'Abramo; J Archambault
Journal:  Open Virol J       Date:  2011-07-04

9.  PaCS is a novel cytoplasmic structure containing functional proteasome and inducible by cytokines/trophic factors.

Authors:  Patrizia Sommi; Vittorio Necchi; Agostina Vitali; Daniela Montagna; Ada De Luigi; Mario Salmona; Vittorio Ricci; Enrico Solcia
Journal:  PLoS One       Date:  2013-12-17       Impact factor: 3.240

10.  In Vitro and In Vivo Synergistic Therapeutic Effect of Cisplatin with Human Papillomavirus16 E6/E7 CRISPR/Cas9 on Cervical Cancer Cell Line.

Authors:  Shuai Zhen; Jiao-Jiao Lu; Li-Jie Wang; Xiao-Min Sun; Jia-Qi Zhang; Xu Li; Wen-Juan Luo; Le Zhao
Journal:  Transl Oncol       Date:  2016-10-28       Impact factor: 4.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.